| Segments |
Note
14—Segments
The
Company has two reportable segments. The legacy segment focuses on the previous endeavors of TNF Pharmaceuticals, Inc. This business
segment operates in the clinical-stage pharmaceutical space and is specifically focused on Isomyosamine (formerly MYMD-1). The second
and primary segment is focused on the development and eventual application of quantum computing technology. The Company’s chief
operating decision maker (“CODM”), who is responsible for evaluating financial performance and allocating resources, is the
Executive Chairman of the Board. The accounting policies of the dual segments are the same as those described in the summary of significant
accounting policies. The CODM does not use assets to assess the segment. The CODM assesses performance for each segment and decides how
to allocate resources based on net operating loss excluding stock-based compensation and warrant issuance expenses. The CODM uses a non-GAAP
measure, net of operating loss excluding stock-based compensation and warrant issuance expenses, as the primary measure of operating
performance and to monitor the Company’s cash burn and adherence to budget.
To
date, the Company has not generated any product revenues and has incurred losses and negative cash flows from operations since inception.
The
following table presents certain financial data for the Company’s two reportable segments and a reconciliation to the Company’s
consolidated net loss.
Schedule
of Reconciliation Consolidated Net Loss
| |
|
|
2026 |
|
|
|
2025 |
|
|
|
2026 |
|
|
|
2025 |
|
| |
|
|
For the Three Months Ended
September 30,
|
|
|
|
For the Nine Months Ended
September 30,
|
|
| |
|
|
2026 |
|
|
|
2025 |
|
|
|
2026 |
|
|
|
2025 |
|
| Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Computing
Technology |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Total
Sales |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Product
Cost of Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Computing
Technology |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Total
Cost of Sales |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Gross
Profit |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Operating
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Administrative
Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
109,757 |
|
|
|
967,833 |
|
|
|
363,001 |
|
|
|
2,703,815 |
|
| Computing
Technology |
|
|
987,815 |
|
|
|
- |
|
|
|
3,267,012 |
|
|
|
- |
|
| Total
Administrative Expenses |
|
|
1,097,572 |
|
|
|
967,833 |
|
|
|
3,630,013 |
|
|
|
2,703,815 |
|
| Research
and Development Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
4,074 |
|
|
|
356,352 |
|
|
|
28,172 |
|
|
|
2,775,337 |
|
| Computing
Technology |
|
|
379,308 |
|
|
|
- |
|
|
|
1,101,877 |
|
|
|
- |
|
| Total
Research and Development Expenses |
|
|
383,382 |
|
|
|
356,352 |
|
|
|
1,130,049 |
|
|
|
2,775,337 |
|
| Stock
Based Compensation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
189,490 |
|
| Computing
Technology |
|
|
860,667 |
|
|
|
- |
|
|
|
5,343,060 |
|
|
|
- |
|
| Total
Stock Based Compensation |
|
|
860,667 |
|
|
|
- |
|
|
|
5,343,060 |
|
|
|
189,490 |
|
| Franchise
Tax Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
12,365 |
|
|
|
200,050 |
|
|
|
34,306 |
|
|
|
200,050 |
|
| Computing
Technology |
|
|
111,289 |
|
|
|
- |
|
|
|
308,751 |
|
|
|
- |
|
| Total
Franchise Tax Expense |
|
|
123,654 |
|
|
|
200,050 |
|
|
|
343,057 |
|
|
|
200,050 |
|
| Warrant
Issuance Expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
-
|
|
|
|
264,417 |
|
|
|
- |
|
|
|
264,417 |
|
| Computing
Technology |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Total
Warrant Issuance Expenses |
|
|
- |
|
|
|
264,417 |
|
|
|
- |
|
|
|
264,417 |
|
| Transaction
costs associated with due diligence |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Computing
Technology |
|
|
100,000 |
|
|
|
- |
|
|
|
100,000 |
|
|
|
- |
|
| Total
Transaction costs associated with due diligence |
|
|
100,000 |
|
|
|
- |
|
|
|
100,000 |
|
|
|
- |
|
| Segment Net Loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
126,196 |
|
|
|
1,788,652 |
|
|
|
425,479 |
|
|
|
6,133,109 |
|
| Computing
Technology |
|
|
2,439,079 |
|
|
|
- |
|
|
|
10,120,700 |
|
|
|
- |
|
| Total
Segment Net Loss |
|
|
2,565,275 |
|
|
|
1,788,652 |
|
|
|
10,546,179 |
|
|
|
6,133,109 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Reconcilement
of Net Loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adjustments
and Reconciling Items |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Interest
and Dividend Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
35,955 |
|
|
|
- |
|
|
|
156,042 |
|
| Computing
Technology |
|
|
55,477 |
|
|
|
- |
|
|
|
227,442 |
|
|
|
- |
|
| Total
Interest and Dividend Income |
|
|
55,477 |
|
|
|
35,955 |
|
|
|
227,442 |
|
|
|
156,042 |
|
| Gain
(Loss) on Sales of Marketable Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
2,176 |
|
| Computing
Technology |
|
|
24,410 |
|
|
|
- |
|
|
|
55,651 |
|
|
|
- |
|
| Total
Gain (Loss) on Sales of Marketable Securities |
|
|
24,410 |
|
|
|
- |
|
|
|
55,651 |
|
|
|
2,176 |
|
| Unrealized
Gain (Loss) on Marketable Securities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
309 |
|
|
|
- |
|
|
|
(1,435 |
)- |
| Computing
Technology |
|
|
2,595 |
|
|
|
- |
|
|
|
(4,695 |
) |
|
|
- |
|
| Total
Unrealized Gain (Loss) on Marketable Securities |
|
|
2,595 |
|
|
|
309 |
|
|
|
(4,695 |
) |
|
|
(1,435 |
)- |
| Change
in Fair Value of Derivative Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
(1,059,000 |
) |
|
|
- |
|
|
|
244,000 |
|
| Computing
Technology |
|
|
1,541,000 |
|
|
|
- |
|
|
|
2,132,000 |
|
|
|
- |
|
| Total
Change in Fair Value of Derivative Liabilities |
|
|
1,541,000 |
|
|
|
(1,059,000 |
) |
|
|
2,132,000 |
|
|
|
244,000 |
|
| Impairment
of Technology License |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
| Computing
Technology |
|
|
- |
|
|
|
- |
|
|
|
(3,177,999 |
) |
|
|
- |
|
| Total
Impairment of Technology License |
|
|
- |
|
|
|
- |
|
|
|
(3,177,999 |
) |
|
|
- |
|
| Total
Adjustments and Reconciling Items: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
- |
|
|
|
(1,022,736 |
)- |
|
|
- |
|
|
|
400,783- |
|
| Computing
Technology |
|
|
1,623,482 |
|
|
|
- |
|
|
|
(767,601 |
) |
|
|
- |
|
| Total
Adjustments and Reconciling Items |
|
|
1,623,482 |
|
|
|
(1,022,736 |
)- |
|
|
(767,601 |
) |
|
|
400,783- |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Consolidated
Net Loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pharmaceuticals |
|
|
(126,196 |
) |
|
|
(2,811,388 |
) |
|
|
(425,479 |
) |
|
|
(5,732,326 |
) |
| Computing
Technology |
|
|
(815,597 |
) |
|
|
- |
|
|
|
(10,888,301 |
) |
|
|
- |
|
| Consolidated
Net Loss |
|
|
(941,793 |
) |
|
|
(2,811,388 |
) |
|
|
(11,313,780 |
) |
|
|
(5,732,326 |
) |
Segment
assets are not reviewed by the CODM and, accordingly, asset information is not presented.
|